Gsk (GLAXF) Total Current Liabilities (2009 - 2026)

Gsk's Total Current Liabilities history runs 18 years deep, the most recent figure standing at -$30.2 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 15.25% year-over-year to -$30.2 billion; the TTM figure through Mar 2026 stood at -$30.2 billion (down 15.25% YoY), while the FY2025 annual figure was -$28.2 billion, down 201.69% from the prior year.
• Total Current Liabilities was -$30.2 billion for Q1 2026 at Gsk, down from -$28.5 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $27.8 billion in Q4 2024 to a low of -$47.6 billion in Q2 2022.
• Historically, Total Current Liabilities has averaged -$17.6 billion across 5 years, with a median of -$26.2 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 75.88% in 2022, then tumbled 273.01% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $26.8 billion in 2022, then decreased by 2.26% to $26.1 billion in 2023, then climbed by 6.5% to $27.8 billion in 2024, then sank by 202.17% to -$28.5 billion in 2025, then retreated by 6.27% to -$30.2 billion in 2026.
• The last three Total Current Liabilities figures came in at -$30.2 billion (Q1 2026), -$28.5 billion (Q4 2025), and -$28.8 billion (Q3 2025), per Business Quant data.